DIABESITY: OBESITY HARBINGER OF DIABETES

Poonam kumari[1]*, Mansi Garg[2], Vikas Chauhan[3], Sachin joshi[4], Sagar[5]

Abstract:
Weight loss has a solid relationship to diabetes and insulin opposition. In fat people, the measure of non-esterified unsaturated fats, glycerol, hormones, cytokines, pro-inflammatory markers, and different substances that are engaged with the improvement of insulin obstruction is expanded. β-islet cell of the pancreas are impaired, causing a lack of control of blood glucose this is the pathogenesis involved in the development of diabetes. Weight decline for resilient people with diabetes has different clinical positive conditions, ordinarily prompts improvement in glucose control and generally, in type 2 diabetes, close to standardization of erratic glucose handling. Weight decrease is difficult to keep up and attempts to get more slender may be undermined by some diabetes prescriptions, for instance, sulfonylurea's, thiazolidinediones and insulin. While lifestyle backing should be the fundamental method to manage help individuals who wish to get fit, pharmacological strategies can similarly be thought of. These incorporate picking glucose-bringing down medications or medication mixes that are weight nonpartisan or result in weight reduction or endorsing drugs that are explicitly affirmed as hostile to heftiness prescription. Given that a portion of the fresher glucose-bringing down prescriptions that cause weight reduction, for example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co transporter 2 inhibitors (SGLT2i), are likewise being utilized or considered for use as antiobesity drugs, it appears to be that the qualification between glucose-bringing down medicine and weight reduction medicine is getting obscured. This audit talks about the fundamental pharmacological methodologies that can be utilized to help weight reduction in people with diabete hence showing that novel obesity specific medicines show guarantee in diabetes the executives and, consequently, their utilization in the treatment of diabetes appears prone to increment after some time.

Keywords: diabetes, insulin resistance, obesity, thiazolinediones.

[1]*Lloyd Institute of Management and Technology (Pharm.), Knowledge Park-ll, Greater Noida, Uttar Pradesh-201306
[2,3,4,5]Department of pharmaceutical sciences, S.G.T College of Pharmacy, SGT University, Gurugram, Haryana, India-122505

***Corresponding Author: -** Poonam Kumari
Lloyd Institute of Management and Technology (Pharm.), Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, Email: patelpoonam785@gmail.com

DOI: 10.48047/ecb/2023.12.si10.00303

Introduction:

Diabetes Mellitus (DM) is a constant issue that can change starch, protein, and fat digestion. It is brought about by the nonattendance of insulin discharge because of either the dynamic or checked powerlessness of the b – Langerhans islet cells of the pancreas to deliver insulin, or because of imperfections in insulin take-up in the fringe tissue. DM is extensively characterized under two classes, which incorporate sort 1 and type 2 diabetes [1].

Type 1 diabetes happens most generally in youngsters, however it can some of the time additionally show up in grown-up age gatherings, especially those in their late thirties and mid-forties. Patients with type 1 diabetes are commonly not corpulent and habitually present with an crisis status known as diabetes ketoacidosis [2] .

Type 2 diabetes represents exactly 90 to 95 percent of all analyzed instances of diabetes. It generally starts as insulin opposition, a problem wherein the cells don't utilize insulin appropriately. As the requirement for insulin rises, the pancreas bit by bit loses its capacity to create insulin[3].

Weight is characterized as a state of unusual or exorbitant fat amassing in fat tissue, to the degree that wellbeing is impaired[4] The measure of overabundance fat in outright term, and its conveyance in the body-either around the midriff and trunk(abdominal , focal or android heftiness) or incidentally around the body(gynoid corpulence) have significant wellbeing suggestions. As a rule, heftiness is related with more serious danger of incapacity or unexpected passing because of type 2 diabets mellitus (T2DM) and cardiovascular infection, for example, hypertention, stroke and coronary illness just as bladder sickness, certain malignancies (endometrial, bosom, prostate, colon) and non deadly conditions including gout, respiratory conditions, gastro-esophageal reflux sickness, osteoarthritis and barrenness. Stoutness likewise conveys serios suggestions for psychosocial wellbeing, mostly because of cultural bias against fatness [5].

Any individual who is overweight and additionally hefty has an insulin obstruction, however…… diabetes just creates in those people who need adequate insulin emission to coordinate the level of insulin opposition. Insulin in those individuals might be high, yet it isn't sufficient to standardize the degree of glycaemia [6] Brokenness of B-cells is a fundamental factor over the movement from prediabetes to diabetes. After the movement from ordinary glucose resilience to anomalous glucose levels increment at first. From that poin t, fasting hyperglycemia may create as the concealment of hepatic gluconeogenesis falls flat [7].

HEFTINESS AND DIABETES INTERLINKED

A solid connection among heftiness and the beginning of diabetes has been accounted for in various examinations. Examination has demonstrated that individuals conveying more weight especially around the belly are more insulin (8-41) safe and may battle to accomplish great diabetes control. [9, 42] Various components have been proposed to connect weight and insulin opposition which incline to diabetes and incorporates expanded Production of adipokines or cytokines including tumor putrefaction factor-resistin and retinol-restricting protein 4 [10].

Additionally, the tissues ability to store glucose as glycogen diminishes and the cells gather more triglycerides rather than glycogen. Moreover, an Indian the muscle to fat ratio is essentially higher than a western partner with comparable BMI and blood glucose level. It has been speculated that overabundance muscle versus fat and low bulk may clarify the high predominance of hyperinsulinemia and the high danger of type-2 diabetes in Asian Indians. The danger of diabetes increments exponentially as BMI increments above about 25kg/m[2,10,11]in a huge cross-sectional examination in moderately aged Indians, a BMI>23 was seen as related with expanded hazard for type 2 diabetes [11].

Insulin opposition prompts raised unsaturated fats in the plasm a, causing diminished glucose transport into the muscle cells, as Instinctive fat expands the danger of diabetes by preferring insulin opposition. Patients with diabetes are typically encouraged to build their physical action and lessen weight. Drawn out span of stoutness likewise effects glucose Homeostasis like expanded protection from glucose removal and diminished emission of insulin. Protection from glucose removal is firmly connected with heftiness and results in high fasting and postload serum insulin fixations. Drawn out span of heftiness could possibly intensify this resistance [12].

MECHANISM OF OBESITY ASSOCIATED INSULIN RESISTANCE

The impact of heaviness on sort 2 diabetes hazard is settled by the level of weight in like manner as by where fat totals. Expanded chest zone fat including typical adiposity, as reflected in slackened up stomach periphery or mid-region to-hip degree, is connected with the metabolic issue, type 2 diabetes, and cardiovascular disease [13]. covered part stay dubious. Regardless of whether subcutaneous fat comes up short on the over the top impact of instinctual fat or is from an overall perspective a more fair dealing with area, for

instance, requires further assessment Past contrasts in muscle versus fat dissemination, imergimg proof propose that diverse sub sorts of fat tissue might be practically particular and influence glucose homeostasis differentially. Grown-up people have restricted and variable quantities of earthy colored fat cells [14] which assume a function in thermogenesis and possibly impact energy use and weight weakness [15].

Atleast three unmistakable systems have been proposed to interface stoutness to insulin opposition and incline to type 2 diabetes : 1) expanded creation of cytokines, including tumor rot factor-a , resistine , and retinol-restricting protein 4 , that add to insulin obstruction just as diminished degrees of adiponectin [16]: 2) ectopic fat statement, especially in the liver and maybe additional skeletal muscle, and the dis-metabolic sequelae [17] : 3) mitochondrial brokenness apparent by decline mitochondrial mass and/or function [18]. Mitochondrial brokenness could be one of numerous significant fundamental imperfection connecting heftiness to diabetes, both by diminishing insulin affectability and by bargaining b-cell function [19].

COMPONENTS UNDERLYING THE EFFECT OF GLUCOSE-LOWERING MEDICATION ON WEIGHT IN TYPE-2 DIABETES

The components prompting weight gain with utilization of insulin (and most likely likewise insulin secretagogues) in people with high blood glucose remember a decrease for vitality misfortune by means of glycosuria, the anabolic impacts of insulin and a related increment in food consumption [20]. The anabolic impacts of insulin are helpful in people who are moderately insulin insufficient, in whom catabolic procedures are profoundly dynamic, for fat people this might be unfavorable, adding to a pattern of weight addition and compounding insulin resistance [21]. Thiazolidinedione related weight gain seems, by all accounts, to be identified with an expansion in fat tissue affidavit in subcutaneous warehouses [22]. In spite of the fact that this class of medications may likewise diminish instinctive fat statement [23]. Along these lines, it is conceivable that the weight gain related with thiazolidinedione utilize might be less destructive than that with other medication classes. The glucose-bringing down medications that bring about weight reduction do as such by adding to a negative vitality balance. For instance, the SGLT2i, which hinder renal glucose transport, initiate loss of about 75g (around 1200 kJ [300 kcal] of glucose in the pee. Nonetheless, the weight reduction coming about because of utilization of SGLT2i is not exactly expected, perhaps due to a compensatory increment in food consumption [24].

INCONVENIENCE THERAPY FOR WEIGHT MANAGEMENT IN TYPE 2 DIABETES

By a wide margin most with diabetes require blend treatment as the condition propels. Given that most are from the earliest starting point started on metformin, the most sensible blends for twofold treatment where weight decrease is essential are metformin+SGLT2i and metformin + GLP-1 RA. In the occasion that triple treatment is required, by then the blend of metformin + SGLT2i + DPP-IVi would give off an impression of being appropriate [25].

There is restricted information on the blend of metformin + SGLT2i + GLP-1 RA yet the after effects of the DURATION 8 examination that a mix of dapagliflozin (a SGLT2i) when every day and eventide (a GLP-1 RA) when week after week on a foundation of metformin treatment brought about a 2% decrease in HbA1c and a weight reduction of 3.4 kg after 28% long stretches of organization; critically, these valuable changes were more prominent after consolidated treatment than when these medications were utilized in monotherapy [26].

In any case, notwithstanding the way that both SGLT2i and GLP-1 RAs have been appeared to diminish insulin prerequisites, improve glycemic control and relieve weight gain when added to treatment for insulin-treated people, current suggestions bolster continuation of metformin with insulin use, except if this is contraindicated [27]. SGLT2i and GLP-1 RAs may have distinctive good conditions when used in diabetes treatment; there is creating evidence that they may diminish natural, particularly hepatic, fat deposition [28].

CURRENTLY AVAILABLE DRUGS FOR OBESITY AND THEIR USES IN DIABETES

When clinically suitable, it is imperative to consider the possible job of drugs that are endorsed for weight the board as extra medicines for individuals with diabetes who wish to get thinner. The utilization of medications for weight treatment has been a dubious theme and various operators have been pulled back after their endorsement, including dexfenfluramine (connections to heart valvular issues), sibutramine (expanded danger of antagonistic cardiovascular occasions) and rimonabant (mind-set issues including suicidality) [29].

A few new specialists/helpful systems have as of late been endorsed for use in the USA and

somewhere else, despite the fact that not all are accessible (1) the GLP-1 RA liraglutide given at a higher portion of 3mg (a most extreme portion of 1.8 mg is recommended for diabetes treatment); (2) the 5-hydroxytriptamine2c (5-HT2c) serotonin receptor agonist locarserin;(3) mix treatment of the halfway acting sympathomimetic phentermine with topiramate; and (4) consolidated treatment with the u-narcotic opponent naltrexone in addition to the noradrenaline (norepinephrine) and dopamine reuptake inhibitor bupropion. Phentermine monotherapy is likewise affirmed for transient utilize just, similar to the utilization of restricted information and won't be examined further [30].

The impact of glucose-lowering drugs on weight in type 1 diabetes

Given that the issue of weight gain with concentrated insulin treatment is known, the choice of including drugs that may constrict this to treatment regimens for type 1 diabetes has been explored in various preliminaries. There is some proof to help metformin use to relieve weight gain in type 1 diabetes, despite the fact that the weight change with metformin has been discovered to be unassuming [31].

Also, in type 1 diabetes associates, preliminaries with GLP-1 RAs have been disillusioning, bringing about just unassuming weight reduction with a unimportant impact on glucose [32]. There has likewise been extensive enthusiasm for the utilization of SGLT2i in type 1 diabetes however starting eagerness has been hosed by the acknowledgment that this class of medications might be related with the improvement of ketoacidosis in powerless people [33].

At present most useful drugs for heftiness in human beings with type 1 diabetes

There are no great preliminaries of heftiness drugs in people with type 1 diabetes. Subsequently, in spite of the fact that the utilization of these medications isn't contraindicated in type 1 diabetes, solution in people with this condition ought to be founded on a cautious assessment and conversation of the expected dangers and advantages. Examinations of the impacts of consolidated treatment with weight-the executives operators and glucose-bringing down medications that additionally cause weight reduction is of expected intrigue, however at present just restricted information is accessible. Affirmed

Table(s)-1 Mechanism of currently approved, investigational and failed drugs for weight management [30].

Endorsed drugs(increase vitality wastage)	**Increment vitality consumption**	**Diminishing food consumption**
· Orlistat (actuates intestinal fat malabsorption)	None	• Liraglutide (GLP-1RA) • Lorcaserin(5-HT2c agonist) • Naltrexone/bupropion • Phentermine/topiramate • Phentermine(short term utilize as it were) • Diethylpropor(short-term utilize as it were)
Under investigation		
• SGLT2i + anorectic medications	· None	• Semaglutide (GLP-1 RA) • GLP-1/glucagon receptor co-agonists • GLP-1/GLP-2 receptor co-agonists • GLP-1/GIP receptor co-agonists • PYY receptor agonists • Selmelanotide (MC4R agonist) • MetAP2 inhibitors (barring beloranib-improvement halted)
Pulledback/improvement suspended		
• Cetilistat (lipase inhibitor; prompts intestinal malabsorption; less compelling than orlistat) • Mitochondrial move protein inhibitors (lessen fat assimilation; cause hepatotoxicity)	• Mitochonialuncoupler(hyperpyrexia) • Thyroid harmones/analogues(toxicity) •B3-adrenoceptor agonists(ineffective)	• fenfluramine, dexfenfluramine • (serotonin-passing on experts; pulled back inferable from heart valvulopathy) • Metreleptin (deficient aside from in leptin need) • Metreletin/pramlintide (deficient) • CCK-A receptor agonists (deficient) • Neuropeptide Y5 receptor rivals (deficient) • Ghrelin rivals (deficient)

EXPLORATORY MEDICINES FOR OBESITY/DIABETES

Phentermine/canagliflozin

As examined beforehand, despite the fact that SGLT2i diminish body weight when utilized for the treatment of type 2 diabetes, weight reduction is not exactly expected, to a great extent due to a compensatory increment in food consumption. It along these lines appears to be intelligent to consolidate SGLT2i with anorexigenic medications. As previously mentioned, when utilized on a metformin foundation, the mix of dapagliflozin with changed delivery exenatide brought about more prominent weight los s than either specialist alone(34). After effects of a stage II preliminary of the mix of phenetermine 15 mg with canagliflozin 300 mg in people without diabetes were as of late detailed; the outcomes demonstrated more prominent weight reduction with blend treatment than with utilization of either specialist alone [35].

Melanocortin 4 receptor agonists

The hypothalamic melanocortin-4 receptor Shows a momentous work in the protocol of food admittance, as displayed by the serious onset phase stoutness found in human being with seized misfortune of function devise and are fortunate in people with MC4R deserts [36].

Methionylamino peptidase 2 inhibitors

Methionylaminopeptidase 2 (MetAP2) is a chemical that is associated with the expulsion of N-methionine deposits from recently incorporated proteins. Irreversible inhibitors of MetAP2, for example, beloranib, were accordingly found to incite critical weight reduction in clinical trials [37].

Gut peptides

The satiety course starts in the gastrointestinal plot and signals from the gut to the mind that control food admissions incorporate supplements, neural signs and hormones. The hormone GLP-1(7-36)amide, which is now being misused for treatment of diabetes and weight, is only one result of the preproglucagon quality; others including oxyntomodulin and glucagon additionally have anorectic impacts. Other gut hormones appeared to lessen food admission in people incorporate cholecystokinin (CCK), peptide YY (3-36) (PYY) and pancreatic polypeptide. The stomach additionally creates the orexigenic peptide ghrelin. The advancement of agonists (or opponents on account of ghrelin) of these peptides has been the focal point of much intrigue [38].

Events of crossover solutions join single particles that follow up on both GLP-1 and glucose-subordinate insulinotropic polypeptide (GIP) receptors, GLP-1 and GLP-2 receptors, or on GLP-1 and glucagon receptors; triple agonists have in like way been made [39].

Table no 2 -Recommended foods for diabesity patients by American Diabetic Association [40]

Protein	**Fruits and vegetables**	**Dairy**	**Grains**
Beans	Berries	low- or nonfat milk	whole grains, such as brown rice and whole-wheat pasta
Nuts	sweet potatoes	low- or nonfat yogurt	
Poultry	nonstarchy vegetables such as asparagus, broccoli, collard greens, kale, and okra		
Eggs			
oily fish such as salmon, mackerel, tuna, and sardines			

Summary and conclusion

Given that most sort 2 diabetes is stoutness related, it bodes well to support treatment procedures that advance weight reduction. It is additionally imperative to consider the utilization of explicit 'hostile to weight' medicines to help a people endeavors at way of life change. Mixes of weight reduction medications and glucose-bringing down

specialists for corpulence/diabetes the executives and the utilization of certain medications in both of these classifications for the two signs obscures the differentiation among stoutness and diabetes medicines. For instance, SGLT2i and GLP-1 RAs are now accessible glucose bringing down operators that advance unassuming decreases in weight and prone to assume a more prominent job in the administration of diabetes later on, particularly given the positive aftereffects of their utilization in ongoing cardiovascular result preliminaries. Then again, novel obesity specific medicines show guarantee in diabetes the executives and, consequently, their utilization in the treatment of diabetes appears prone to increment after some time.

Reference:

1. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clinica Belgica. 2003 Dec 1;58(6):335-41.
2. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Archives of internal medicine. 2007 Jul 23;167(14):1545-51.
3. Koche LS. Obesity and its Treatments.
4. Garrow JS. Obesity and related diseases. Churchill Livingstone; 1988.
5. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiological reviews. 1994 Oct;74(4):761-811.
6. Røder ME, Porte Jr D, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 1998 Feb 1;83(2):604-8.
7. Porte Jr D. β-cells in type II diabetes mellitus. Diabetes. 1991 Feb 1;40(2):166-80.
8. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England journal of medicine. 2013 Jul 11;369(2):145-54.
9. Pratley RE, Weyer C, Bogardus C. Metabolic abnormalities in the development of noninsulin-dependent diabetes mellitus. In: LeRoith D, Taylor sl, et al. editors Diabetes mellitus. Philadelphia: Lippincot-Raven Publishers;2000:548557.
10. Pandya H, Lakhani JD, Patel N. Obesity is becoming synonym for diabetes in rural areas of india also an alarming situation. Int J Biol Med Res.. 2011 Apr 30;2(2):556-60.
11. Care D. Jan: 33 Suppl. 1: S62-S69.". Diagnosis and classification of diabetes mellitus." American Diabetes Association. 2010.
12. Care D. Jan: 33 Suppl. 1: S62-S69.". Diagnosis and classification of diabetes mellitus." American Diabetes Association. 2010.
13. Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. The Lancet. 2011 Mar 26;377(9771):1085-95.
14. Björntorp P. Metabolic implications of body fat distribution. Diabetes care. 1991 Dec 1;14(12):1132-43.
15. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM. Identification and importance of brown adipose tissue in adult humans. New England journal of medicine. 2009 Apr 9;360(15):1509-17.
16. Frontini A, Cinti S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell metabolism. 2010 Apr 7;11(4):253-6.
17. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Academy of Sciences. 2010 Nov;1212(1):E1-9.
18. Larson-Meyer DE, Newcomer BR, Ravussin E, Volaufova J, Bennett B, Chalew S, Cefalu WT, Sothern M. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia. 2011 Apr;54:869-75.
18. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-452 CrossRef PubMed Google Scholar
19. Bagdade JD, Bierman EL, Porte D. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. The Journal of clinical investigation. 1967 Oct 1;46(10):1549-57.
20. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes, Obesity and Metabolism. 2007 Nov;9(6):799-812.
21. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism-Clinical and Experimental. 2002 Mar 1;51(3):314-7.
22. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance.

International Journal of Clinical Practice. 2006 Oct;60(10):1272-80.
23. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium–glucose cotransporter 2 inhibition. Diabetes care. 2015 Sep 1;38(9):1730-5.
24. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Bjerre Knudsen L. Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight. Diabetes, Obesity and Metabolism. 2012 Jun;14(6):531-8.
25. De Block C. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination. The Lancet Diabetes & Endocrinology. 2018 May 1;6(5):349-52.
26. Wilding JP, Bain SC. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. Diabetic Medicine. 2016 Jul;33(7):864-76.
27. Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA 1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58:1183-7.
28. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015 Nov 26;373(22):2117-28.
29. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016 Nov 10;375(19):1834-44.
30. Wilding JP. Medication use for the treatment of diabetes in obese individuals. Diabetologia. 2018 Feb;61(2):265-72.
31. Liu W, Yang XJ. The effect of metformin on adolescents with type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials. International journal of endocrinology. 2016 Jul 12;2016.
32. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology. 2016 Mar 1;4(3):221-32.
33. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes care. 2015 Sep 1;38(9):1687-93.
34. Janssen Research and Development (2016) Effects of co-administration of canagliflozin 300mg and phentermine 15mg with placebo in the treatment of non-diabetic overweight and obese participants. Available from http://clinicaltrials.gov/ct2/show/results/NCT02243202. Accessed 29 December 2016
35. Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. New England Journal of Medicine. 2016 Jul 21;375(3):240-6.
36. Kim DD, Krishnarajah J, Lillioja S, De Looze F, Marjason J, Proietto J, Shakib S, Stuckey BG, Vath JE, Hughes TE. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes, Obesity and Metabolism. 2015 Jun;17(6):566-72.
37. Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Disease models & mechanisms. 2012 Sep 1;5(5):621-6.
38. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature medicine. 2015 Jan;21(1):27-36.
39. Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell metabolism. 2016 Jul 12;24(1):51-62.
40. Medically reviewed by Peggy Pletcher, M.S., R.D., L.D.,CDE- Written by Jamie Heidel- Updated on February 7, 2020.
41. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. Journal of Epidemiology & Community Health. 2005 Feb 1;59(2):134-9.
42. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clinical chemistry. 2008 Jun 1;54(6):945-55.